Company intelligence / Profile preview

Ypsomed

Burgdorf, BE, Switzerlandypsomed.com ↗

Ownership: Public · YPSN
Employees: ~2800
Development stage: Other

Overview

Ypsomed is a global leader in developing and manufacturing innovative self-injection and infusion systems. Its products—including insulin pumps and autoinjectors—are widely used in diabetes care and other therapeutic areas requiring injectable medications. The company's platforms enable pharmaceutical partners to deliver new biologic drugs via self-administration. It has over 40 years of experience with a strong track record in innovation.

Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Insulet (OmniPod distribution)Dexcom (CGM integration)Dongbao Biotech (Gansulin pen)numerous pharmaceutical/biotech companies

Financials

Market cap: $218.6M
Total revenue: $87.7M

Beyond the preview

Go deeper on Ypsomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ypsomed.

Explore the full profile